<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897091</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000528264</org_study_id>
    <secondary_id>S8814A-ICSC</secondary_id>
    <secondary_id>GHI-01-024</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <nct_id>NCT00897091</nct_id>
  </id_info>
  <brief_title>S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil</brief_title>
  <official_title>Molecular Predictors of Outcome on CAF Plus Tamoxifen Versus Tamoxifen Alone in Postmenopausal Women With Node Positive, Receptor Positive Breast Cancer [NCI Correlative Science Reference No. # 8814A-ICSC]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may&#xD;
      help doctors learn more about changes that occur in DNA and identify biomarkers related to&#xD;
      cancer. It may also help doctors predict how patients will respond to treatment.&#xD;
&#xD;
      PURPOSE: This laboratory study is looking at biomarkers in predicting outcome in&#xD;
      postmenopausal women with hormone receptor-positive, node-positive breast cancer treated with&#xD;
      tamoxifen with or without cyclophosphamide, doxorubicin, and fluorouracil.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the value of the Oncotype DX Recurrence Score for prediction of treatment&#xD;
           benefit of cyclophosphamide, doxorubicin hydrochloride, and fluorouracil (CAF)&#xD;
           chemotherapy, in terms of disease-free survival (DFS) and overall survival (OS), in&#xD;
           postmenopausal patients with estrogen and/or progesterone receptor-positive,&#xD;
           node-positive breast cancer treated on clinical trial SWOG-8814.&#xD;
&#xD;
        -  Determine the overall prognostic value of the Oncotype DX Recurrence Score, in terms of&#xD;
           DFS and OS, in patients treated with tamoxifen citrate alone or CAF with concurrent or&#xD;
           sequential tamoxifen citrate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the optimal cut point (i.e., low, intermediate, and high recurrence risk) for&#xD;
           the Recurrence Score in these patients.&#xD;
&#xD;
        -  Determine the relationship between expression of any one of the 21 genes on the Oncotype&#xD;
           DX gene panel with DFS and OS.&#xD;
&#xD;
        -  Determine whether the expression of any of these genes are associated with CAF treatment&#xD;
           benefit.&#xD;
&#xD;
        -  Determine the relationship between the Oncotype DX Recurrence Score and DFS and OS in&#xD;
           multivariate models, including number of positive nodes, tumor size, tumor grade,&#xD;
           estrogen receptor, progesterone receptor, and HER2 and p53 status.&#xD;
&#xD;
        -  Determine the relationship between quantitative reverse-transcriptase-polymerase chain&#xD;
           reaction expression of up to 800 additional genes and prognosis and/or prediction of CAF&#xD;
           benefit.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Fixed paraffin-embedded breast tumor tissue samples (obtained from the SWOG Central Tumor&#xD;
      Repository at the University of Colorado) are analyzed by the Oncotype DX panel containing&#xD;
      the following 21 genes: BAG1, Bc12, CCNB1, CD68, SCUBE2, CTSL2, Esrt1, GRB7, GSTM1, HER2,&#xD;
      Ki-67, MYBL2, PR, STK15, STMY3, SURV, B-actin, GAPDH, GUS, RPLPO, and TFRC. The Oncotype DX&#xD;
      Recurrence Score is calculated for each patient. Analyses are performed to determine the&#xD;
      relationship between the Recurrence Score and gene expression and prognosis/prediction of&#xD;
      therapy (tamoxifen citrate alone or cyclophosphamide, doxorubicin hydrochloride, and&#xD;
      fluorouracil with concurrent or sequential tamoxifen citrate) benefit as well as to determine&#xD;
      the relationship between clinical and demographic covariates and disease-free and overall&#xD;
      survival.&#xD;
&#xD;
      Samples are also analyzed by reverse-transcriptase-polymerase chain reaction for exploratory&#xD;
      analysis of up to 800 additional genes that may be prognostic and/or predict the likelihood&#xD;
      of therapy benefit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distant disease-free recurrence</measure>
  </secondary_outcome>
  <enrollment type="Actual">750</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>comparative genomic hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>microarray analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>reverse transcriptase-polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients consenting to banking in S8814&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
               -  Node-positive disease (pT1-3a, pN1-2 [clinical N0-1], M0)&#xD;
&#xD;
          -  Previously enrolled in SWOG-8814, a treatment clinical trial, and in SWOG-9445, a&#xD;
             companion tissue banking study&#xD;
&#xD;
          -  Tumor block or unstained sections available from initial diagnosis in the SWOG archive&#xD;
&#xD;
               -  Sufficient tumor in block or unstained sections&#xD;
&#xD;
               -  Patients for whom only unstained slides are available must have acceptable&#xD;
                  reverse-transcriptase-polymerase chain reaction (RT-PCR) profiles&#xD;
&#xD;
          -  Sufficient RNA (≥ 300 ng) for RT-PCR analysis with the Oncotype DX 21 gene assay&#xD;
&#xD;
          -  Average normalized cycle threshold for the 5 reference genes ≤ 35&#xD;
&#xD;
          -  Follow-up data from the SWOG-8814 clinical trial obtained from the patient&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen and/or progesterone receptor positive tumor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy S. Albain, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center at Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>May 28, 2013</last_update_submitted>
  <last_update_submitted_qc>May 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

